QIAGEN Revenue 2010-2022 | QGEN

QIAGEN annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • QIAGEN revenue for the quarter ending September 30, 2022 was $0.500B, a 6.57% decline year-over-year.
  • QIAGEN revenue for the twelve months ending September 30, 2022 was $2.226B, a 0.65% decline year-over-year.
  • QIAGEN annual revenue for 2021 was $2.252B, a 20.39% increase from 2020.
  • QIAGEN annual revenue for 2020 was $1.87B, a 22.53% increase from 2019.
  • QIAGEN annual revenue for 2019 was $1.526B, a 1.64% increase from 2018.
QIAGEN Annual Revenue
(Millions of US $)
2021 $2,252
2020 $1,870
2019 $1,526
2018 $1,502
2017 $1,418
2016 $1,338
2015 $1,281
2014 $1,345
2013 $1,302
2012 $1,254
2011 $1,170
2010 $1,087
2009 $1,010
QIAGEN Quarterly Revenue
(Millions of US $)
2022-09-30 $500
2022-06-30 $516
2022-03-31 $628
2021-12-31 $582
2021-09-30 $535
2021-06-30 $567
2021-03-31 $567
2020-12-31 $571
2020-09-30 $484
2020-06-30 $443
2020-03-31 $372
2019-12-31 $413
2019-09-30 $383
2019-06-30 $382
2019-03-31 $349
2018-12-31 $403
2018-09-30 $378
2018-06-30 $377
2018-03-31 $344
2017-12-31 $397
2017-09-30 $364
2017-06-30 $349
2017-03-31 $308
2016-12-31 $367
2016-09-30 $339
2016-06-30 $334
2016-03-31 $298
2015-12-31 $349
2015-09-30 $315
2015-06-30 $319
2015-03-31 $298
2014-12-31 $360
2014-09-30 $336
2014-06-30 $331
2014-03-31 $317
2013-12-31 $361
2013-09-30 $322
2013-06-30 $315
2013-03-31 $304
2012-12-31 $347
2012-09-30 $304
2012-06-30 $307
2012-03-31 $296
2011-12-31 $334
2011-09-30 $289
2011-06-30 $282
2011-03-31 $264
2010-12-31 $286
2010-09-30 $274
2010-06-30 $263
2010-03-31 $264
2009-12-31 $289
2009-09-30 $260
2009-06-30 $240
2009-03-31 $221
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.120B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.477B 10.28
GSK (GSK) United Kingdom $69.125B 8.67
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.592B 0.00
Arcus Biosciences (RCUS) United States $1.934B 29.03
Biohaven (BHVN) United States $1.080B 0.00
Emergent Biosolutions (EBS) United States $0.594B 4.67
Zymeworks (ZYME) Canada $0.494B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.276B 0.00
Enzo Biochem (ENZ) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00